Cumberland Pharmaceuticals Inc. CPIX

Full chart Compare
Set alert

Price alert · CPIX

All alert types
4.31 USD +0.09 (+2.13%)

At closeNov 3, 2026, 4:00 PM EST

4.27 -0.04 -0.97%

After hours · Nov 3, 4:00 PM ET

4.19 Day range 4.42
1.85 52-week range 9.28
YTD
+8.29%
1 year
+56.16%
Market cap
64.58M
Revenue (ttm)
36.79M
Profit margin
-29.55%
EPS (ttm)
-0.62
Shares out
14.04M
Forward P/E
16.07
YTD return
+8.29%
1-year return
+56.16%
Volume
215.21K
Avg volume
81.04K
Open
4.28
Previous close
4.22
Day's range
4.19 – 4.42
52-week range
1.85 – 9.28
Beta
0.22

5D -0.12 (-2.76%)

4.505TueWedFriMon4.22

Key statistics

Enterprise value
35.51M
PEG ratio
0.00
Price / sales
0.86
Price / book
1.27
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-9.90%
Free cash flow
3.91M
Total cash
17.46M
Total debt
21.48M
Return on equity
-36.07%
Short % of float
2.09%
50-day average
1.40
200-day average
1.48

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
CPIX Revenue — quarterly 166.46K
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CPIX Net income — quarterly -4.28M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CPIX EPS — quarterly -0.29
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

CPIX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 20240.00-0.02——
Aug 6, 2024Jun 1, 20240.000.01——
May 7, 2024Mar 1, 20240.00-0.05——
Mar 5, 2024Dec 1, 20230.00-0.11——
Nov 7, 2023Sep 1, 20230.000.02——
Aug 8, 2023Jun 1, 20230.000.16——

Upgrades / downgrades

CPIX analyst upgrades and downgrades
DateFirmActionFromTo
Dec 3, 2019B. Riley Securitiesmain—Buy
Nov 18, 2019B. Riley Securitiesmain—Buy
Aug 17, 2018B. Riley SecuritiesmainBuyBuy
Apr 17, 2018B. Riley Securitiesinit—Buy
Apr 10, 2013UBSmain—Neutral
Nov 12, 2012UBSmain—Neutral

About Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States

News

Your note

Sign in to keep a note on CPIX — it syncs with the Stock Master app.

Insider holders

CPIX insider holders
InsiderRelationLatest transactionDateShares held
BROWN MARTIN S JRDirectorStock Award(Grant)Mar 24, 20246,000
GALANTE JOSEPH C.DirectorStock Award(Grant)Mar 24, 202459,356
JONES JAMES RDirectorPurchaseNov 28, 202439,377
KAZIMI A. J.Chief Executive OfficerPurchaseNov 28, 20245,701,530
KROGULSKI KENNETH JDirectorPurchaseNov 28, 2024271,627
YOUNG CAROLINE RDirectorPurchaseNov 28, 202429,664

Institution ownership

CPIX institution ownership
Holder% heldSharesValueReported
Renaissance Technologies, LLC3.76%528,1631.19MSep 29, 2024
Vanguard Group Inc2.67%374,251842.06KSep 29, 2024
Bridgeway Capital Management, Inc.2.04%286,655644.97KSep 29, 2024
Dimensional Fund Advisors LP2.02%284,005639.01KSep 29, 2024
Acadian Asset Management. LLC1.34%188,164423.37KSep 29, 2024
Blackrock Inc.0.78%110,068247.65KSep 29, 2024

Fund ownership

CPIX fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.00%280,820631.85KSep 29, 2024
Bridgeway Funds Inc-Ultra Small Company Fund1.66%233,068524.40KSep 29, 2024
Vanguard Extended Market Index Fund0.60%84,244189.55KSep 29, 2024
DFA U.S. Targeted Value Portfolio0.57%79,720179.37KJul 30, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.36%49,887112.25KSep 29, 2024
DFA U.S. Micro Cap Series0.34%47,772107.49KJul 30, 2024